AMRN

AmarinC

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-03

View Chart

AI scenario view

RankAlpha Sentiment AI

B+

Bull case

20%

Probability

Target price

$20.57

+41.6% vs current

Most likely

Base case

60%

Probability

Target price

$15.82

+8.9% vs current

B-

Bear case

20%

Probability

Target price

$11.07

-23.8% vs current

AI sentiment snapshot

Latest data as of 2026-01-11

AI commentary

Sentiment is cautious-to-negative: published analyst targets cluster around $12, below the anchor, indicating sell-side skepticism. Market tone is binary—regulatory or litigation wins would unlock upside, while adverse outcomes would compress valuation and sustain downside pressure [#SERP-1].

RankAlpha Sentiment AI - 2026-01-11

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-04-11catalystQuarterly commercial / earnings updateHigh impact

Quarterly results or a commercial update could materially revise revenue trajectory and guidance; consensus price-targets cited below remain below current anchor, which could trigger analyst downgrades or upgrades [#SERP-1].

2026-06-30eventAnalyst consensus revisions / target resetsHigh impact

Wall Street consensus (many sources ~ $12) is materially below the anchor; a coordinated set of target downgrades or a lone upgrade could move the stock; dates for next round of revisions are not fixed—using conservative window end [#SERP-1], [#SERP-6].

2027-01-11catalystLong-term commercial/patent/competitive outcomeHigh impact

Longer-term outcomes (competitive generic entry, patent/litigation resolution, or sustained commercial recovery) will determine multi-year valuation; market currently appears to price downside in consensus targets cited [#SERP-5].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-01-11 • Updated nightlySource: Internal modelMethodology